Cancer

Mouse studies suggest LPA could enhance the efficacy of chemotherapies and anti-PD-1 immunotherapies to treat brain and lung cancers. In a mouse model of glioma, LPA plus the generic chemotherapy temozolomide increased survival compared with temozolomide alone, and LPA plus an anti-PD-1 mAb increased survival compared with the anti-PD-1 antibody alone. In a mouse model of Lewis lung carcinoma (LLC), LPA plus the anti-PD-1 mAb decreased tumor growth. In a mouse model of brain-metastatic LLC, LPA plus the generic chemotherapy 5-FU increased survival compared with 5-FU alone. Next steps could include testing LPA plus other chemotherapies or immunotherapies in models of brain and lung cancers...